Differences in treatment response in bronchial epithelial cells from idiopathic pulmonary fibrosis (IPF) patients: a first step towards personalized medicine?
Idiopathic pulmonary fibrosis (IPF) has a detrimental prognosis despite antifibrotic therapies to which individual responses vary. IPF pathology is associated with oxidative stress, inflammation and increased activation of SRC family kinases (SFK). This pilot study evaluates individual responses to...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 February 2023
|
| In: |
Antioxidants
Year: 2023, Jahrgang: 12, Heft: 2, Pages: 1-14 |
| ISSN: | 2076-3921 |
| DOI: | 10.3390/antiox12020443 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/antiox12020443 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2076-3921/12/2/443 
|
| Verfasserangaben: | C. Veith, M.A. Schneider, L. Maas, A. van der Vliet, F.J. van Schooten, M. Kreuter, M. Meister, A.W. Boots and N. Kahn |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1842050559 | ||
| 003 | DE-627 | ||
| 005 | 20230706213440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230412s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/antiox12020443 |2 doi | |
| 035 | |a (DE-627)1842050559 | ||
| 035 | |a (DE-599)KXP1842050559 | ||
| 035 | |a (OCoLC)1389530849 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Veith, Carmen |e VerfasserIn |0 (DE-588)1285973445 |0 (DE-627)1842052837 |4 aut | |
| 245 | 1 | 0 | |a Differences in treatment response in bronchial epithelial cells from idiopathic pulmonary fibrosis (IPF) patients |b a first step towards personalized medicine? |c C. Veith, M.A. Schneider, L. Maas, A. van der Vliet, F.J. van Schooten, M. Kreuter, M. Meister, A.W. Boots and N. Kahn |
| 264 | 1 | |c 10 February 2023 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.04.2023 | ||
| 520 | |a Idiopathic pulmonary fibrosis (IPF) has a detrimental prognosis despite antifibrotic therapies to which individual responses vary. IPF pathology is associated with oxidative stress, inflammation and increased activation of SRC family kinases (SFK). This pilot study evaluates individual responses to pirfenidone, nintedanib and SFK inhibitor saracatinib, markers of redox homeostasis, fibrosis and inflammation, in IPF-derived human bronchial epithelial (HBE) cells. Differentiated HBE cells from patients with and without IPF were analyzed for potential alterations in redox and profibrotic genes and pro-inflammatory cytokine secretion. Additionally, the effects of pirfenidone, nintedanib and saracatinib on these markers were determined. HBE cells were differentiated into a bronchial epithelium containing ciliated epithelial, basal, goblet and club cells. NOX4 expression was increased in IPF-derived HBE cells but differed on an individual level. In patients with higher NOX4 expression, pirfenidone induced antioxidant gene expression. All drugs significantly decreased NOX4 expression. IL-6 (p = 0.09) and IL-8 secretion (p = 0.014) were increased in IPF-derived HBE cells and significantly reduced by saracatinib. Finally, saracatinib significantly decreased TGF-β gene expression. Our results indicate that treatment responsiveness varies between IPF patients in relation to their oxidative and inflammatory status. Interestingly, saracatinib tends to be more effective in IPF than standard antifibrotic drugs. | ||
| 650 | 4 | |a IPF | |
| 650 | 4 | |a nintedanib | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a pirfenidone | |
| 650 | 4 | |a primary bronchial epithelial cells | |
| 650 | 4 | |a saracatinib | |
| 700 | 1 | |a Schneider, Marc |d 1982- |e VerfasserIn |0 (DE-588)140634401 |0 (DE-627)620239948 |0 (DE-576)319208095 |4 aut | |
| 700 | 1 | |a Maas, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a van der Vliet, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a van Schooten, F. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 700 | 1 | |a Meister, Michael |e VerfasserIn |0 (DE-588)1078792046 |0 (DE-627)839461402 |0 (DE-576)451890108 |4 aut | |
| 700 | 1 | |a Boots, A. W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kahn, Nicolas |d 1982- |e VerfasserIn |0 (DE-588)1023650371 |0 (DE-627)718423941 |0 (DE-576)367217635 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antioxidants |d Basel : MDPI, 2013 |g 12(2023), 2, Artikel-ID 443, Seite 1-14 |h Online-Ressource |w (DE-627)737287578 |w (DE-600)2704216-9 |w (DE-576)379466627 |x 2076-3921 |7 nnas |a Differences in treatment response in bronchial epithelial cells from idiopathic pulmonary fibrosis (IPF) patients a first step towards personalized medicine? |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:2 |g elocationid:443 |g pages:1-14 |g extent:14 |a Differences in treatment response in bronchial epithelial cells from idiopathic pulmonary fibrosis (IPF) patients a first step towards personalized medicine? |
| 856 | 4 | 0 | |u https://doi.org/10.3390/antiox12020443 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2076-3921/12/2/443 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230412 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1023650371 |a Kahn, Nicolas |m 1023650371:Kahn, Nicolas |d 50000 |e 50000PK1023650371 |k 0/50000/ |p 9 |y j | ||
| 998 | |g 1078792046 |a Meister, Michael |m 1078792046:Meister, Michael |d 910000 |d 950000 |d 950900 |e 910000PM1078792046 |e 950000PM1078792046 |e 950900PM1078792046 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 7 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |e 50000PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 6 | ||
| 998 | |g 140634401 |a Schneider, Marc |m 140634401:Schneider, Marc |d 910000 |d 950000 |d 950900 |e 910000PS140634401 |e 950000PS140634401 |e 950900PS140634401 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 2 | ||
| 999 | |a KXP-PPN1842050559 |e 4307677560 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 19.02.13"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2013 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Antioxidants","subtitle":"open access journal","title_sort":"Antioxidants"}],"recId":"737287578","disp":"Differences in treatment response in bronchial epithelial cells from idiopathic pulmonary fibrosis (IPF) patients a first step towards personalized medicine?Antioxidants","origin":[{"dateIssuedKey":"2013","publisher":"MDPI","dateIssuedDisp":"2013-","publisherPlace":"Basel"}],"id":{"issn":["2076-3921"],"zdb":["2704216-9"],"eki":["737287578"]},"part":{"issue":"2","year":"2023","extent":"14","text":"12(2023), 2, Artikel-ID 443, Seite 1-14","volume":"12","pages":"1-14"}}],"note":["Gesehen am 12.04.2023"],"name":{"displayForm":["C. Veith, M.A. Schneider, L. Maas, A. van der Vliet, F.J. van Schooten, M. Kreuter, M. Meister, A.W. Boots and N. Kahn"]},"recId":"1842050559","id":{"doi":["10.3390/antiox12020443"],"eki":["1842050559"]},"origin":[{"dateIssuedDisp":"10 February 2023","dateIssuedKey":"2023"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"extent":"14 S."}],"person":[{"family":"Veith","role":"aut","given":"Carmen","display":"Veith, Carmen"},{"role":"aut","given":"Marc","family":"Schneider","display":"Schneider, Marc"},{"display":"Maas, L.","role":"aut","given":"L.","family":"Maas"},{"display":"van der Vliet, A.","family":"van der Vliet","given":"A.","role":"aut"},{"role":"aut","given":"F. J.","family":"van Schooten","display":"van Schooten, F. J."},{"display":"Kreuter, Michael","family":"Kreuter","given":"Michael","role":"aut"},{"family":"Meister","given":"Michael","role":"aut","display":"Meister, Michael"},{"display":"Boots, A. W.","role":"aut","given":"A. W.","family":"Boots"},{"display":"Kahn, Nicolas","given":"Nicolas","role":"aut","family":"Kahn"}],"title":[{"subtitle":"a first step towards personalized medicine?","title":"Differences in treatment response in bronchial epithelial cells from idiopathic pulmonary fibrosis (IPF) patients","title_sort":"Differences in treatment response in bronchial epithelial cells from idiopathic pulmonary fibrosis (IPF) patients"}]} | ||
| SRT | |a VEITHCARMEDIFFERENCE1020 | ||